1
Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus
Condition(s):Atrophy; Vaginal DiseasesLast Updated:May 21, 2018Completed
Hide Studies Not Open or Pending
Condition(s):Atrophy; Vaginal DiseasesLast Updated:May 21, 2018Completed
Condition(s):Atrophy; Vaginal DiseasesLast Updated:May 21, 2018Completed
Condition(s):Atrophy; Vaginal DiseasesLast Updated:May 18, 2018Completed
Condition(s):Atrophy; Vaginal DiseasesLast Updated:June 28, 2013Completed
Condition(s):Atrophy; Vaginal DiseasesLast Updated:May 18, 2018Completed
Condition(s):Atrophy; Vaginal DiseasesLast Updated:June 28, 2013Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.